Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Palliat Care ; 22(1): 129, 2023 Sep 06.
Article in English | MEDLINE | ID: mdl-37670312

ABSTRACT

BACKGROUND: The Emergency Department (ED) is not always the optimal place for people with palliative care needs but is the most common route for treatment when urgent care is sought. The aim of this study,''REasons for PalLIative Care Admissions (REPLICA)' was to explore the perspectives of ED healthcare professionals of hospital admission or discharge via ED for palliative care patients. METHODS: This is a sequential mixed methods study comprising (i) quantitative descriptive analysis of Hospital Episode Statistics (HES) of palliative care patients (code Z51.5) who were admitted through ED in a West Midlands Hospital and for the rest of England; (ii) in-depth semi-structured interviews with 17 ED staff which were analysed using thematic content analysis. RESULTS: Over the four years (2013-2017), 430,116 people admitted through ED were identified with a Z51.5 diagnosis code, 0.6% (n = 2736) of whom were from the West Midlands Hospital. The most common reasons for palliative care patients' admission to hospitals across England were for care of chronic kidney disease, cancers and urinary tract infections. Five themes were elicited from the qualitative analysis: (1) Providing palliative care in ED is challenging, due to factors including lack of training in palliative care and the unsuitable environment. (2) Patients go to ED due to challenges in community management such as inappropriate referrals and no care plan in place. (3) Health system influences admission and discharge decisions, including bed availability and being unable to set up community services out-of-hours. (4) Discussion with patient about treatment and end of life care needs to be outside of ED whilst the patient is still well enough to express their wishes. (5) Improving services for patients with palliative care needs. Recommendations include short training sessions for ED staff and accessing palliative care professionals 24/7. CONCLUSIONS: A large number of palliative care patients visit ED and are admitted to hospital for care; there is an urgent need to prevent patients attending the hospital through the establishment of a coordinated and dedicated service to support palliative care patients in the community.


Subject(s)
Hospitals , Palliative Care , Humans , Emergency Service, Hospital , England , Delivery of Health Care
2.
JEMS ; 41(5): 13, 2016 May.
Article in English | MEDLINE | ID: mdl-27301089
3.
Appl Environ Microbiol ; 82(13): 4006-4016, 2016 07 01.
Article in English | MEDLINE | ID: mdl-27129967

ABSTRACT

UNLABELLED: The blue wavelengths within the visible light spectrum are intrinisically antimicrobial and can photodynamically inactivate the cells of a wide spectrum of bacteria (Gram positive and negative) and fungi. Furthermore, blue light is equally effective against both drug-sensitive and -resistant members of target species and is less detrimental to mammalian cells than is UV radiation. Blue light is currently used for treating acnes vulgaris and Helicobacter pylori infections; the utility for decontamination and treatment of wound infections is in its infancy. Furthermore, limited studies have been performed on bacterial biofilms, the key growth mode of bacteria involved in clinical infections. Here we report the findings of a multicenter in vitro study performed to assess the antimicrobial activity of 400-nm blue light against bacteria in both planktonic and biofilm growth modes. Blue light was tested against a panel of 34 bacterial isolates (clinical and type strains) comprising Acinetobacter baumannii, Enterobacter cloacae, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Enterococcus faecium, Klebsiella pneumoniae, and Elizabethkingia meningoseptica All planktonic-phase bacteria were susceptible to blue light treatment, with the majority (71%) demonstrating a ≥5-log10 decrease in viability after 15 to 30 min of exposure (54 J/cm(2) to 108 J/cm(2)). Bacterial biofilms were also highly susceptible to blue light, with significant reduction in seeding observed for all isolates at all levels of exposure. These results warrant further investigation of blue light as a novel decontamination strategy for the nosocomial environment, as well as additional wider decontamination applications. IMPORTANCE: Blue light shows great promise as a novel decontamination strategy for the nosocomial environment, as well as additional wider decontamination applications (e.g., wound closure during surgery). This warrants further investigation.


Subject(s)
Bacteria/drug effects , Biofilms/drug effects , Light , Microbial Viability/drug effects , Colony Count, Microbial , Wounds and Injuries/microbiology
4.
Burns ; 41(8): 1683-1694, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26188884

ABSTRACT

UNLABELLED: Antimicrobial medicated dressings (AMD) are often used to reduce bacterial infection of burns and other wounds. However, there is limited literature regarding comparative efficacies to inform effective clinical decision making. OBJECTIVES: Following on from a previous study where we demonstrated good antibiofilm properties of acetic acid (AA), we assessed and compared the in vitro anti-biofilm activity of a range of AMDs and non-AMDs to AA. METHODS: Laboratory experiments determined the ability of a range of eleven commercial AMD, two nAMD, and AA, to prevent the formation of biofilms of a panel of four isolates of Pseudomonas aeruginosa and Acinetobacter baumannii. RESULTS: There is a large variation in ability of different dressings to inhibit biofilm formation, seen between dressings that contain the same, and those that contain other antimicrobial agents. The best performing AMD were Mepilex(®) Ag and Acticoat. AA consistently prevented biofilm formation. CONCLUSIONS: Large variation exists in the ability of AMD to prevent biofilm formation and colonisation of wounds. A standardised in vitro methodology should be developed for external parties to examine and compare the efficacies of commercially available AMDs, along with robust clinical randomised controlled trials. This is essential for informed clinical decision-making and optimal patient management.


Subject(s)
Acinetobacter baumannii/drug effects , Anti-Bacterial Agents/pharmacology , Bandages , Biofilms/drug effects , Burns/therapy , Pseudomonas aeruginosa/drug effects , Acetic Acid/pharmacology , Acetic Acid/therapeutic use , Acinetobacter Infections/prevention & control , Acinetobacter baumannii/growth & development , Anti-Bacterial Agents/therapeutic use , Biofilms/growth & development , Burns/microbiology , Chlorhexidine/pharmacology , Chlorhexidine/therapeutic use , Honey , In Vitro Techniques , Iodine/pharmacology , Iodine/therapeutic use , Microbial Sensitivity Tests , Polyesters/therapeutic use , Polyethylenes/therapeutic use , Pseudomonas Infections/prevention & control , Pseudomonas aeruginosa/growth & development , Silver/pharmacology , Silver/therapeutic use , Wound Infection/prevention & control
5.
Consult Pharm ; 24(5): 392-4, 2009 May.
Article in English | MEDLINE | ID: mdl-19555148

ABSTRACT

Recent data regarding cardiovascular risks have raised serious safety concerns with thiazolidinedione (rosiglitazone and pioglitazone) therapy. Some studies have identified an increased risk of myocardial infarction and death with rosiglitazone use; others found no increased risk. Multiple comorbidities (heart failure, renal insufficiency) limit diabetes treatment options in the elderly. It is estimated that more than 30% of nursing facility residents have diabetes; therefore, pharmacists can benefit from a review of safety concerns with thiazolidinediones. Research findings reported by the media can be misinterpreted by laypersons, making pharmacists an integral resource in answering concerns about thiazolidinedione safety.


Subject(s)
Cardiovascular Diseases/etiology , Hypoglycemic Agents/adverse effects , Thiazolidinediones/adverse effects , Age Factors , Aged , Diabetes Mellitus, Type 2/drug therapy , Humans , Hypoglycemic Agents/therapeutic use , Pioglitazone , Risk Factors , Rosiglitazone , Thiazolidinediones/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...